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Abstract Using affinity chromatography on lactose-agarose, 
five l~-galactoside binding lectins of 14 to 20 kDa were detected 
in the rat small intestinal mucosa. The prominant proteins of 17 
and 19 kDa were purified to homogeneity by 2D-electrophoresis. 
Direct N-terminal sequencing of the 17 kDa protein and intra- 
chain sequencing of the 19 kDa protein produced sequences which 
are part of the N-terminal domain of the L-361galectin-4. A rabbit 
polyclonal antibody was raised against the 19 kDa lectin, which 
specifically recognized the 17 and 19 kDa lectins and detected a 
related 36 kDa protein in human undifferentiated HT29 cells. 
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I. Introduction 
Galectins represent a growing family of abundant fl-galacto- 
side binding lectins which share characteristic amino acid se- 
quences [1]. Though their function is not yet known with cer- 
tainty, they could play important roles in many cellular or cell- 
matrix interactions through specific recognition of carbohy- 
drate structures [2]. Many fl-galactoside binding lectins have 
been described in the rat intestine [3], but few of them were fully 
characterized. Particularly, a 17 kDa lectin, named RIH, has 
been purified and led to the isolation of a cDNA sequence 
encoding a 36 kDa lectin [3,4], now recognized as galectin 4, 
consisting of two carbohydrate binding domains bound by a 
link sequence and the C-terminal domain II being the R IH 
sequence. During the purification of an rat intestinal en- 
dogenous proteins inhibitor of fucosyltransferase activity (fuc- 
tinin (fuctinin [5]), preliminary experiments were performed to 
rule out the possibility that fuctinin could be an endogenous 
lectin inhibiting fucosyltransferase activity by interaction with 
galactoside-substrates. A lectin fraction, different from fuc- 
tinin, was obtained which also inhibited in vitro fucosyltrans- 
ferase activity in a non-competitive way [6]. To get more infor- 
mation about the inhibition of this glycosylation process [7], a 
more refined study of this lectin fraction was undertaken, which 
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ered saline; SDS-PAGE, sodium dodecylsulfate polyacrylamide gel 
electrophoresis; TBS, Tris-buffered saline; TST, Tris-buffered saline 
containing 0.1% Tween 20 and 10% fetal calf serum. 
led to the purification of the N-terminal domanin I of galectin 
4 and to the generation of specific antibodies against this do- 
main. 
2. Materials and methods 
2.1. Purification of fl-galactoside binding lectins from rat intestine 
Scraped small intestinal mucosa of adult male Sprague-Dawley rats 
was homogeneized at 4°C in a buffer consisting of 50 mM Tris-HC1, 
150 mM Lactose, 4 mM 2-mercaptoethanol, pH 7.5, containing 2 mM 
EDTA and 0.25 mM PMSF to inhibit protease activities. Purification 
of the lectin fraction from mucosa was essentially performed as de- 
scribed by Leffler et al. [3], with the addition of an ammonium sulfate 
fractionation step (80% saturation) for lactose elimination before af- 
finity chromatography. After dialysis of the pellet and removal of insol- 
uble proteins by centrifugation, the soluble fraction was loaded onto 
a column of Lactose-Agarose (Sigma, USA) equilibrated in 50 mM 
Tris-HC1, pH 7.5, 100 mM NaC1 (buffer A), washed with four column 
volumes of buffer A and one column volume of buffer A containing 100 
mM sucrose. Lectins were eluted with buffer A containing 100 mM 
lactose. Protein concentration i  the fractions was determined by the 
method of Schaffner and Weissmann [8] and analyzed by sodium do- 
decyl sulfate-polyacrylamide slab gel electrophoresis (SDS-PAGE). 
2.2. Gel electrophoreses 
For proteins, SDS-PAGE was performed under reducing conditions 
by the method of Laemmli [9], using a 15% separating gel at a constant 
power of 6 W for 2 h. Peptide lectrophoresis was carried out according 
to the method of Schagger and von Jagow [10] using a 10% stacking 
gel, a 5% spacer gel and a 15% separating gel. Two-dimensional electro- 
phoreses (2D-electrophoreses) were carried out according to O'Farrel 
for equilibrium (IEF) [11] and for non-equilibrium (NEPHGE) [12] pH 
gradient electrophoreses. 
2.3. Amino acid sequence determinations and analysis 
Lectins isolated by 2D-electrophoresis in non-equilibrium conditions 
were blotted onto PVDF membranes (Immobilon pSQ, Millipore, USA) 
according to Matsudaira [13] for direct sequencing. For the 19 kDa 
lectin, PVDF spots were incubated overnight with 10 mg/ml of CNBr 
in 70% HCOOH. Generated peptides were eluted, separated by electro- 
phoresis and blotted onto PVDF membranes. Edman analysis of pro- 
tein or peptide spots was performed at the Service Central d'Analyses 
of the Centre National de la Recherche Scientifique (CNRS, Solaize, 
France). 
2.4. Production of a specific antibody against he purified 19 kDa lectin 
Pieces of wet polyacrylamide g l containing the 19 kDa lectin were 
used for rabbit immunization [14]. Before injection, 10 ml of blood was 
collected as preimmune control serum. For the initial injection, the 
suspension of polyacrylamide g l containing 150/tg of the 19 kDa lectin 
was emulsified in an equal volume of complete Freund's adjuvant [15]. 
Booster injections with 75/lg lectin without Freund's adjuvant were 
performed one and two months later. Diluted immune serum was used 
as a source of antibodies without further purification. 
2.5. Immunoblotting 
SDS PAGE separated proteins were transferred onto nitrocellulose 
sheets using a semi-dry electrophoretic blotting apparatus (Sartorius, 
France) at 0.9 mA/cm 2for 90 min [16]. The sheets were incubated in 
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50 mM Tris-HC1, pH 7.5, 150 mM NaC1 (TBS) containing 0.1% Tween 
20 and 10% newborn calf serum (TST), for 30 min to block non-specific 
antibody binding. After a 2 h incubation in the presence of rabbit 
immune serum diluted to 112,000 in TST followed by several washings 
with TST, the bound rabbit antibodies were detected by incubation with 
alkaline phosphatase-labeled goat anti-rabbit IgG (Dako, Denmark)• 
Control blots with preimmune s rum performed in each case. 
2.6. Protein staining 
Proteins were stained with Coomassie brillant blue R-250 and molec- 
ular weight markers blotted on membranes with Protogold (Biocell 
Research Laboratories, UK). 
2.7. HT29 cells 
Undifferentiated HT29 cells (from ATCC, USA) were cultured in 
DMEM medium (Sigma) supplemented with 10% calf serum• At con- 
fluency, cells were collected on PBS buffer, pH 7.4 (8 mM Na2HPO4, 
1.5 mM KH2PO 4, 137 mM NaC1, 2.7 mM KC1) by scraping and washed 
three times with the same buffer. Cells were made more fragile by 10 
min treatment at 4°C with 0.25 M sucrose, 10 mM triethanolamine 
buffer, pH 7.0, then cells were broken by 20 strokes of a Potter-E1- 
vejhem homogeneizer. 
3. Results 
Preliminary experiments were conducted inorder to optimize 
the preparation ofmucosal intestinal lectins by affinity chrom- 
atography on Lactose Agarose. The best yield (3% of soluble 
proteins of intestinal mucosa) was obtained with a ratio of 4 mg 
of intestinal soluble proteins for 1 ml of affinity phase. The yield 
sharply decreased using higher ratio, falling down to 1% with 
a load of 12 mg proteins/ml affinity phase. Analysis of the lectin 
fraction by SDS-PAGE indicated the presence of five protein 
bands in the 14-20 kDa range (Fig. 1, left), with two prominent 
bands at 17 and 19 kDa (named thereafter 17 and 19 kDa 
lectins). Two rows of spots at 17 and 19 kDa were present on 
the IEF-2D electrophoresis gel (Fig. 1, right top panel). Under 
non-equilibrium conditions the 2D electrophoresis pattern 
shows less numerous spots (Fig. 1, right bottom panel): the 17 
kDa lectin consisted of a major spot at pH 7.6 (lower arrow- 
head) and several more basic proteins around pH 8.2 8.3; for 
the 19 kDa lectin, a major spot appeared at pH 7.3 (upper 
arrowhead) and two minor spots at pH 7.1 and 7.8. Just above 
the 19 kDa major spot, two small spots were also present. The 
reproducibility of this pattern allowed us to use NEPHGE for 
preparative purpose: the major spot of both 17 and 19 kDa 
lectins were either used for antibody generation orblotted onto 
PVDF membranes for microsequencing. 
Direct microsequencing of the 17 kDa lectin provided an 
unambiguous NH2-terminal sequence (YNPTLPYKRPIPGG- 
LSVGMSIYIQG) which was found to correspond to amino 
acids 13 37 of the domain-I of L36, a previously characterized 
36 kDa lectin. Direct sequencing of the 19 kDa lectin was 
unsuccessful, despite treatment of a larger amount of protein 
than for the 17 kDa lectin. Peptides of the 19 kDa lectin were 
generated by CNBr cleavage of the blotted spot. After peptide 
separation and blotting, a sequence of 23 amino acids was 
obtained for one peptide (RRFHVNFEVGQDEGADIAFHF- 
NP), which completely matched the amino acids 44-66 of the 
same L36 lectin. A possible structural relationship of both the 
17 and 19 kDa lectin with the L-36 lectin and the RIH lectin 
are shown in Fig. 2. 
Production of polyclonal antibodies from gel pieces was un- 
dertaken in the rabbit for the 19 kDa lectin (used spot is indi- 
cated by arrowhead in the right bottom panel of Fig. 1), which 
produced a powerful and highly specific antiserum. Intense 
staining of both 17 and 19 kDa lectins was obtained by Western 
blotting with a 1/2,000 dilution of the antiserum. On blots from 
soluble intestinal mucosa proteins as well as from the lectin 
fraction, only the 17 and 19 kDa lectins were detected (Fig. 3, 
left and middle panel). No binding of the antiserum to a 36 kDa 
component was ever observed espite repeated experiments 
under various conditions. In undifferentiated HT29 cells, the 
antiserum produced a quite different: amajor protein at 36 kDa 
and one minor protein at 22 kDa were specifically detected in 
the soluble extract of the HT-29 cells (Fig. 3, right panel). 
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Fig. 1. Characterization f the lectin fraction from rat small intestinal mucosa. Left panel: SDS-PAGE analysis of the lectin fraction obtained by 
lactose-agarose affinity chromatography. (a)Calibration kit; (b) total soluble proteins: (c) lectin fraction. Right top panel: 2D-electrophoresis in 
equilibrium condition (IEF) of the lectin fraction. Right bottom panel: 2D-electrophoresis in non-equilibrium condition (NEPHGE); black arrows 
show the 17 and 19 kDa spots used for microsequencing and antibody production• Alkaline pH of the 2D-gels are located at the right side. 
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Fig. 2. Structural relationship between lectin 19 kDa, lectin 17 kDa, 
RIH lectin and the 36 kDa lectin (Galectin 4). Amino acid numbers are 
referred to the numerotation famino acids of the 36 kDa lectin [4]. 
4. Discussion 
This work on intestinal lectins was initiated [6] before the 
publication of the extensive work by Oda et al. [4] concerning 
molecular cloning of L36 (galectin 4) of the rat intestine and 
was pursued thereafter since the protein pattern of the lectin 
fraction that we prepared from rat intestine was different from 
that previously reported in the same organ by Leffier et al. [3]. 
The two major lectins we purified originated from the N-termi- 
nal domain I of galectin 4, whereas the major lectin purified by 
Leffler et al. [3], called RIH, corresponds to the C-terminal 
domain II of this galectin. Only minor differences existed be- 
tween the two purification procedures: in our case, we use 
ammonium sulphate precipitation for lactose elimination, a 
commercially available lactose agarose and perhaps adifferent 
ratio (protein load/phase volume) in affinity chromatography. 
As reported by Leffler et al. [3], this ratio is critical in lectin 
purification and we used the ratio giving the best yield for the 
preparation used. The yield of 3% of soluble protein for the 
lectin fraction was higher than previously reported (1% [3]). Use 
of scraped mucosa instead of whole intestine could be reponsi- 
ble for the higher yield and the different pattern in our work 
as compared to the study of Leffler et al. [3]. Oda et al. [4] raised 
the question about he fate of the N-terminal domain of galectin 
4 which they were unable to detect. Obviously, our work dem- 
onstrates that a large amount of the N-terminal fragment of 
galectin 4 is present in intestinal mucosa. Conversely, the 17 
kDa C-terminal domain of galectin 4 (RIH) could not be de- 
tected in our preparation, though, since its pHi is above 9, it 
might correspond to the minor basic protein observed on NEP- 
HGE gels. 
From the work of Oda et al. [4], the rat intestine xpresses 
the full-length mRNA of galectin 4 and the 36 kDa lectin can 
be immunodetected on blots after extraction under denaturing 
conditions. Therefore, the obtention of separate domains prob- 
ably depends on proteolytic leavage during homogeneization 
and purification, despite the use of two protease inhibitors. 
However, this cleavage appeared to be remarkably constant, 
since 2D-electrophoresis produced the same pattern in many 
independent preparations. Moreover, unambiguous sequence 
of the 17 kDa and 19 kDa lectins were obtained espite pooling 
of lectin fractions from independent experiments. Whether this 
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cleavage can also occur physiologically and lead to functional 
lectins generated from the 36 kDa lectin can only be hypothet- 
ized. 
Other post-translational modifications of galectin 4 can be 
suspected. The blocking of the N-terminal end of the 19 kDa 
lectin precluded N-terminal sequencing. Though N-terminal 
blocking can be artificially produced uring sample processing, 
it could be physiologically relevant: N-terminal blocking was 
also reported for several lectins isolated by ion-exchange 
chromatography [3]and N-terminal acetylation of galectin 3 
has been demonstrated [17]. Thus, the N-terminal blocked 
19 kDa lectin could likely correspond to the complete domain 
I of galectin 4. On IEF-2D gels, both 17 and 19 kDa lectins 
appeared as two rows of spots of quite similar molecular mass. 
In non-equilibrium conditions, most of these spots became 
gathered in one major spot for each lectin and Edman's reac- 
tion (directly or after hydrolysis) indicated a single N-terminal 
sequence in this spot. This fact might be interpreted as a differ- 
ental but limited proteolysis of the C-terminal part of domain 
I, since the link sequence between the two domains of galectin 
is very susceptible toproteolysis [1]; it could also suggest other 
post- translational modifications trongly altering protein 
charge such as phosphorylation a d sulfatation. For example, 
phosphorylation has been described for CBP35 (galectin 3) in 
the mouse and the dog [18,19]. 
That the 17 and 19 kDa proteins belong to the same galectin 
was confirmed by the production of an anti-19 kDa protein 
antibody which specifically recognized both lectins. Of interest 
is the cross reaction of this antibody to a human protein of 36 
kDa extracted from undifferentiated HT29 cells derived from 
a human colonic adenocarcinoma [20] and which could likely 
be the human conterpart of the galectin 4. By contrast, Oda et 
al. [4] could not detect any hybridization ofrat galectin 4cDNA 
with human DNA. However, at the protein level, rat and 
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Fig. 3. Immunoblotting using the anti-19 kDa lectin antiserum. Left 
panel: immunoblotting after SDS-PAGE of soluble proteins of small 
intestinal mucosa; (a) preimmune s rum; (b,c,d) immune serums after 
the first, the second and the third boost injection, respectively. Middle 
panel: immunoblotting of the lectin fraction obtained by lactose-aga- 
rose affinity chromatography (letters as above). Right panel: im- 
munoblotting of soluble proteins from human undifferentiated HT29 
cells. 
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human galectin 4 could share sufficient homologies at least in 
the N-terminal domain to give such a cross reaction. This high- 
light antibody provides a powerful tool for further studies of 
galectin 4 in rat and human tissues. 
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